Brief: ReNerve Says Quarterly Sales Rose By 80% Compared To Corresponding Quarter
30/01/2026 01:38
Jan 30 (Reuters) - ReNerve Ltd RNV.AX: QUARTERLY SALES ROSE BY 80% COMPARED TO CORRESPONDING QUARTER IN FY25 Further company coverage: RNV.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Renerve
See all newsBrief: Renerve Says Positive FDA Feedback On Nervalign Nerve Guide Matrix
Brief: Renerve And Rmit Awarded A$499K Grant
Brief: ReNerve Posts Full-Year Loss Attributable Of A$5.6 Million
Brief: ReNerve Says Nervalign Nerve Cuff Receives CDSCO Marketing Approval In India
Australia's ReNerve rises on securing up to A$5 million funding facility